

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF TEXAS

FILED

MAY 20 1999

NANCY DOHERTY, CLERK
BY P. Hunter
Deputy

UNITED STATES OF AMERICA)

v.)

F. HOFFMANN-LA ROCHE LTD)

Defendant.)

Criminal No. 99-CR-184-R

Filed:

Violation: 15 U.S.C. § 1

Judge:

PLEA AGREEMENT

The United States of America and F. Hoffmann-La Roche Ltd ("Roche") hereby enter into the following Plea Agreement pursuant to Rule 11(e)(1)(C) of the Federal Rules of Criminal Procedure ("Fed. R. Crim. P.");

RIGHTS OF DEFENDANT

1. Roche understands its right:

(a) to be represented by an attorney;

(b) to be charged by indictment;

(c) to plead not guilty to any criminal charge brought against it;

(d) to have a trial by jury, at which it would be presumed not guilty of the charge and the United States would have to prove it guilty beyond a reasonable doubt;

(e) to confront and cross-examine witnesses against it and to subpoena witnesses in its defense at trial;

(f) as a corporation organized and existing under the laws of Switzerland, to contest service of the summons in this case, and to contest the

jurisdiction of the United States to prosecute this case against it in the United States District Court;

(g) to appeal its conviction if it is found guilty at trial; and

(h) to appeal the imposition of sentence against it.

**AGREEMENT TO PLEAD GUILTY
AND WAIVE CERTAIN RIGHTS**

2. Roche waives the rights set out in Paragraph 1(b)-(g) above. Roche also waives the right to appeal the imposition of sentence against it, so long as the sentence imposed is consistent with the recommendation in Paragraph 8 of this Plea Agreement. Pursuant to Rule 7(b), Fed. R. Crim. P., Roche will waive indictment and plead guilty pursuant to Fed. R. Crim. P. 11(e)(1)(C) to a one-count Information, to be filed in the United States District Court for the Northern District of Texas. The Information will charge Roche with participating in a conspiracy to suppress and eliminate competition by fixing, increasing, and maintaining the price and allocating the volume of certain vitamins sold in the United States and elsewhere, and allocating among corporate conspirators certain contracts for vitamin premixes for customers located throughout the United States through the submission of rigged and non-competitive bids for such contracts, beginning in part at least as early as January 1990 and continuing in part into February 1999, in violation of the Sherman Antitrust Act, 15 U.S.C. § 1.

3. Pursuant to the terms of this Plea Agreement, Roche will plead guilty at arraignment to the criminal charge described in Paragraph 2 above, and will make a factual admission of guilt to the Court in accordance with Rule 11, Fed. R. Crim. P., as set forth in Paragraph 4 below.

FACTUAL BASIS FOR OFFENSE CHARGED

4. Had this case gone to trial, the United States would have presented evidence to prove the following facts.

(a) For purposes of this Plea Agreement, the "relevant period" is that period beginning as early as January 1990 and continuing into February 1999. Throughout the relevant period, Roche was a corporation organized and existing under the laws of Switzerland. During the relevant period, Roche was a manufacturer of various vitamins used to enrich human food, pharmaceutical products, and animal feed in the United States and elsewhere. During the relevant period, Roche was engaged in the sale of these vitamins to the United States and elsewhere.

(b) During the relevant period, Roche, through several of its executives, officers, and employees, participated in a conspiracy with other vitamin manufacturers, the primary purpose of which was to fix, increase, and maintain the price and allocate the volume of, certain vitamins sold in the United States and elsewhere, and to allocate customers in the United States. In furtherance of the conspiracy, Roche, through a number of its executives, officers, and employees, engaged in conversations and attended meetings with representatives of other vitamin manufacturers. During such meetings and conversations, agreements were reached as to the prices at which the conspirators would sell certain vitamins and the timing of price increases, and the volumes of certain vitamins they would sell in the United States and

elsewhere. Further, agreements were reached as to the submission of rigged bids for the award and performance of contracts to supply certain vitamin premixes to customers located throughout the United States.

(c) During the relevant period, vitamins that were the subject of this conspiracy and sold by one or more of the conspirator firms, and equipment and supplies necessary to the production and distribution thereof, as well as payments therefor, traveled in interstate and foreign commerce. The business activities of Roche and its co-conspirators, in connection with the production and sale of the vitamins affected by this conspiracy, were within the flow of, and substantially affected, interstate and foreign trade and commerce.

(d) Substantial quantities of vitamins affected by this conspiracy were sold by conspirators to customers in the Northern District of Texas.

POSSIBLE MAXIMUM SENTENCE

5. Roche understands that the maximum penalty which may be imposed against it upon conviction for a violation of the Sherman Antitrust Act is a fine in an amount equal to the largest of:

- (a) \$10 million (15 U.S.C. § 1);
 - (b) twice the gross pecuniary gain derived from the crime; or
 - (c) twice the gross pecuniary loss caused to the victims of the crime
- (18 U.S.C. § 3571(d)).

6. In addition, Roche understands that:

- (a) pursuant to §8B1.1(a)(2) of the United States Sentencing

Commission Guidelines ("U.S.S.G."), the Court may order it to pay restitution to the victims of the offense;

(b) pursuant to 18 U.S.C. § 3013(a)(2)(B), the Court is required to order the defendant to pay a four hundred dollar (\$400) special assessment upon conviction for the charged crime; and

(c) a term of probation of at least one year, but not more than five years, may be imposed (18 U.S.C. § 3561(c)(1)).

SENTENCING GUIDELINES

7. Sentencing for the offense to be charged will be conducted pursuant to the U.S.S.G. manual in effect on the day of sentencing. Pursuant to U.S.S.G. §1B1.8, self-incriminating information provided to the United States pursuant to this Plea Agreement will not be used in determining the applicable Guidelines range, except to the extent provided for in U.S.S.G. § 1B1.8(b).

SENTENCING AGREEMENT

8. Pursuant to Rule 11(e)(1)(C), Fed. R. Crim. P., the United States and Roche agree that the appropriate disposition of the case is, and agree jointly to recommend that the Court impose, pursuant to 18 U.S.C. § 3571, a sentence requiring Roche to pay a fine to the United States in the amount of five hundred million dollars (\$500,000,000) payable in full within 120 days of imposition of sentence.

(a) Roche understands that the Court will order it to pay a four hundred dollar (\$400) special assessment pursuant to 18 U.S.C. § 3013(a)(2)(B) and U.S.S.G. §8E1.1 in addition to any fine imposed.

(b) In light of the pendency of civil causes of actions which potentially provide for a recovery of a multiple of actual damages, it is the view of both parties to this agreement that the complication and prolongation of the sentencing process that would result from an attempt to fashion a proper restitution order outweigh the need to provide restitution to any victims (see 18 U.S.C. § 3663(a)(1)(B)(ii)). Therefore, the United States agrees that it will not seek a restitution order with respect to the offense charged in the Information.

(c) The United States and Roche jointly submit that this Plea Agreement, together with the record that will be created by the United States and Roche at sentencing and the further disclosure described in Paragraph 10 of this Plea Agreement, provides sufficient information concerning Roche, the offense charged in this case, and Roche's role in the offense to enable the meaningful exercise of sentencing authority by the Court under 18 U.S.C. § 3553. The United States and Roche will jointly request that the Court accept Roche's guilty plea and immediately impose sentence on the day of arraignment pursuant to the provisions of Rule 32(b)(1), Fed. R. Crim. P., and U.S.S.G. § 6A1.1. The Court's denial of the request to impose sentence immediately based upon the record provided by Roche and the United States will not void this Plea Agreement.

9. The United States and Roche understand that the Court retains complete discretion to accept or reject the agreed-upon recommendation provided for in this Plea

Agreement. If the Court does not accept the recommended sentence, this Plea Agreement will be void and Roche will be free to withdraw its guilty plea (Fed. R. Crim. P. 11(e)(4)). If Roche does withdraw its plea of guilty, this Plea Agreement, the guilty plea, and any statements made in connection with or in furtherance of the plea or this Plea Agreement, or in the course of discussions leading to the plea or the Plea Agreement, shall not be admissible against Roche in any criminal or civil proceeding (Fed. R. Crim. P. 11(e)(6)).

10. The United States, prior to sentencing in the case, will fully advise the Court of all facts relating to Roche's involvement in the charged offense, all other relevant conduct, and subject to the full and continuing cooperation of Roche described in Paragraph 12 of this Plea Agreement, the fact, manner, and extent of Roche's ongoing cooperation and its commitment to prospective cooperation with the United States' investigation and prosecutions.

11. The United States and Roche agree that the Guidelines fine range exceeds the agreed-upon recommended fine. The United States agrees that, based upon Roche's past and ongoing cooperation, the United States will make a motion pursuant to U.S.S.G. §8C4.1 requesting that the Court depart from the sentence otherwise provided for, pursuant to the U.S.S.G. and impose the agreed-upon sentence set out above because of the substantial assistance provided by Roche in the investigation of alleged violations of federal criminal law in the vitamins industry. The decision to file a motion pursuant to U.S.S.G. §8C4.1 lies within the sole discretion of the United States.

ROCHE'S COOPERATION

12. Roche and its parent, affiliates and subsidiaries (related entities) will fully and truthfully cooperate with the United States in the prosecution of this case, the conduct of the current federal investigation of violations of the federal antitrust and related criminal laws in the vitamins industry, any other federal investigation resulting therefrom, and any litigation or other proceedings arising or resulting from any such investigation to which the United States is a party ("Federal Proceeding"). Such cooperation shall include, but not be limited to:

(a) producing to the United States all documents, information, and other materials, wherever located, in the possession, custody, or control of Roche or any of its related entities, requested by the United States in connection with any Federal Proceeding;

(b) securing the ongoing, full and truthful cooperation, as defined in Paragraph 13 of this Plea Agreement, of Daniel Jabas, Product Manager; Peter Schlumpf, Product Manager; Bruno Müller, Vitamin Business Unit Manager; and Jacques Epars, Product Manager, including making such persons available in the United States and at other mutually agreed-upon locations, at Roche's expense, for interviews and the provision of testimony in grand jury, trial and other judicial proceedings in connection with any Federal Proceeding.

(c) using its best efforts to secure the ongoing, full and truthful cooperation, as defined in paragraph 13 of this Plea Agreement, of the current and former directors, officers, and employees of Roche or its related entities, in

addition to those specified in subparagraph (b) above, as may be requested by the United States, including making such persons available in the United States and at other mutually agreed-upon locations, at Roche's expense, for interviews and the provision of testimony in grand jury, trial and other judicial proceedings in connection with any Federal Proceeding.

13. The ongoing, full, and truthful cooperation of each person described in paragraph 12(b) or 12(c) above will be subject to the procedures and protections of this paragraph, and shall include, but not be limited to:

(a) producing in the United States and at other mutually agreed-upon locations all documents (including claimed personal documents) and other materials requested by attorneys and agents of the United States;

(b) making himself or herself available for interviews in the United States, and at other mutually agreed-upon locations, upon the request of attorneys and agents of the United States;

(c) responding fully and truthfully to all inquiries of the United States in connection with any Federal Proceeding, without falsely implicating any person or intentionally withholding any information;

(d) otherwise voluntarily providing the United States with any materials or information, not requested in (a) - (c) of this paragraph, that he or she may have related to any such Federal Proceeding; and

(e) when called upon to do so by the United States, testifying in trial and grand jury or other proceedings in the United States, fully, truthfully and

under oath, subject to the penalties of perjury (18 U.S.C. § 1621), making false statements or declarations in grand jury or court proceedings (18 U.S.C. § 1623), contempt (18 U.S.C. §§ 401-402), and obstruction of justice (18 U.S.C. § 1503), in connection with any such Federal Proceeding.

GOVERNMENT'S AGREEMENT

14. The United States agrees to the following:

(a) Subject to the exceptions noted in Paragraph 14(d), the United States will not bring criminal charges against any current or former director, officer, or employee of Roche or its related entities (except for Roland Brönnimann, President, Vitamins and Fine Chemicals Division; Andreas Hauri, former Executive Vice President and Head of Global Marketing; Kuno Sommer, former Executive Vice President and Head of Global Marketing; and, a former Roche executive identified in a sealed Addendum filed in conjunction with this Plea Agreement, who are all specifically excluded from each and every term of paragraphs 12, 13 and 14 of this Plea Agreement) for any act or offense committed prior to the date of this Plea Agreement and while such person was a director, officer, or employee of Roche or its subsidiaries, that was undertaken in furtherance of any attempted or completed antitrust conspiracy involving the sale of vitamins or in connection with any investigation thereof ("Relevant Offense").

(b) Should the United States determine that any current or former director, officer, or employee of Roche or its related entities may have information relevant to any Federal Proceeding, the United States may request such person's cooperation pursuant to the terms of this Plea Agreement by written request delivered to counsel for the individual (with a copy to the undersigned counsel for Roche) or, if the individual is not known by the United States to be represented, to the undersigned counsel for Roche.

(c) The United States agrees that when any person travels to the United States for interviews, grand jury appearances or court appearances pursuant to this Plea Agreement, the United States will take no action, based upon any offense subject to this Plea Agreement, to subject such person to arrest, service of process or prevention from departing the United States. This paragraph does not apply to an individual's commission of perjury (18 U.S.C. § 1621), making a false statement or declaration in grand jury or court proceedings (18 U.S.C. § 1623), obstruction of justice (18 U.S.C. § 1503) or contempt (18 U.S.C. §§ 401-402) in connection with any testimony provided pursuant to this Plea Agreement in trial, grand jury or other judicial proceedings in the United States.

(d) In the event that any person requested to provide cooperation pursuant to Paragraph 14(b) fails to comply with such person's obligations under Paragraph 13 of this Plea Agreement, the terms of this Plea Agreement as they pertain to such person shall be rendered null and void, and the agreement not to

prosecute such person granted in this Plea Agreement shall be void.

(e) Except as provided in Paragraph 14(f), information provided to the United States pursuant to the terms of this Plea Agreement pertaining to any Relevant Offense, or any information directly or indirectly derived from such information, may not be used against such person in a criminal case, except a prosecution for perjury (18 U.S.C. § 1621), making a false statement or declaration in grand jury or court proceedings (18 U.S.C. § 1623), contempt (18 U.S.C. §§ 401-402, and obstruction of justice (18 U.S.C. § 1503).

(f) In the event a person who provides information to the United States pursuant to this Plea Agreement fails to comply fully with his obligations under Paragraph 13 of this Plea Agreement, the agreement in Paragraph 14(e) not to use such information, or any information directly or indirectly derived from such information, against such person in a criminal case shall be void.

(g) The non-prosecution terms of this paragraph do not apply to any civil liability to the United States, to any violation of the federal tax or securities laws, or to any crime of violence.

15. Upon acceptance of the guilty plea called for by this Plea Agreement, imposition of the agreed-upon sentence, and subject to the cooperation requirements of Paragraph 12 of this Plea Agreement, the United States agrees that it will not bring further criminal charges against Roche or its related entities for any Relevant Offense. The non-prosecution terms of this paragraph do not apply to any civil liability to the United States, to any violation of the federal tax or securities laws, or

to any crime of violence.

16. Roche understands that it may be subject to administrative or other action by governmental agencies other than the United States Department of Justice, Antitrust Division, based upon any conviction resulting from this Plea Agreement, and that this Plea Agreement in no way controls whatever action, if any, such other agencies may take. However, the United States Department of Justice, Antitrust Division, agrees that, if requested, it will advise the appropriate officials of any governmental agency considering such action against Roche or its related entities, based upon a Relevant Offense or conviction resulting from this Plea Agreement, of the fact, manner, and extent of the cooperation of Roche, as described herein, as a matter for such agency to consider before determining what action, if any, to take with regard to Roche.

REPRESENTATION BY COUNSEL

17. Roche has been represented by counsel and is fully satisfied that its attorneys have provided competent legal representation. Roche has thoroughly reviewed this Plea Agreement and acknowledges that counsel has advised it of the nature of the charges, any possible defenses to the charges, and the nature and range of possible sentences.

VOLUNTARY PLEA

18. Roche's decision to enter into this Plea Agreement and Roche's decision to tender a plea of guilty are freely and voluntarily made and are not the result of force, threats, assurances, promises, or representations other than the representations contained in this Plea Agreement. There have been no promises or representations to Roche as to whether the Court will accept or reject this Plea Agreement.

VIOLATION OF PLEA AGREEMENT

19. Roche agrees that, should the United States determine in good faith, during the period any Federal Proceeding is pending, that Roche has failed to provide full cooperation (as described in Paragraph 12 of this Plea Agreement) or otherwise has violated any other provision of this Plea Agreement, the United States may void any of its obligations under this Plea Agreement (except its obligations under this paragraph) by notifying counsel for Roche in writing by personal or overnight delivery, or facsimile transmission.

ENTIRETY OF AGREEMENT

20. This Plea Agreement constitutes the entire agreement between the United States and Roche concerning the disposition of the criminal charges in this case. This Plea Agreement cannot be modified except in writing signed by the United States and Roche.

21. The undersigned corporate representatives of Roche are authorized to enter this Plea Agreement on behalf of Roche as evidenced by the Resolution of the Executive Committee of Roche attached hereto and incorporated herein by reference.

22. A facsimile signature shall be deemed an original signature for the purpose of executing this Plea Agreement.

DATED:


Respectfully submitted,




GREGORY S. GLOFF
MITCHELL R. CHITWOOD

Attorneys, Antitrust Division
U.S. Department of Justice
Dallas Field Office
Thanksgiving Tower
1601 Elm Street, Suite 4950
Dallas, TX 75201-4717
Tel.: (214) 880-9401

FOR DEFENDANT F. Hoffmann-La Roche Ltd



SCOTT W. MULLER
Counsel for F. Hoffmann-La Roche Ltd
Davis Polk & Wardwell
450 Lexington Avenue
New York, NY 10017
(212) 450-4000



F. Hoffmann-La Roche Ltd